Evogene Ltd.

https://www.evogene.com

Evogene Ltd. is an Israeli computational chemistry company that specializes in the generative design of small molecules for the pharmaceutical and agricultural industries. Headquartered in Rehovot, Israel, the company's mission is to revolutionize product development in life sciences by leveraging its proprietary Computational Predictive Biology (CPB) platform and its core generative AI engine, ChemPass AI™.

At the heart of Evogene's offerings is ChemPass AI™, which is designed to create novel, highly potent small molecules optimized across multiple critical parameters, thereby improving success rates and reducing development time and costs. The company applies this technology across various market segments, including human health for drug discovery and agriculture for the development of ag-chemicals. While Evogene previously advanced product pipelines through subsidiaries in areas such as human microbiome-based therapeutics (Biomica), medical cannabis (Canonic), ag-biologicals (Lavie Bio), and castor oil production (Casterra), it has recently undergone a strategic refocus.

In 2025, Evogene initiated a strategic transformation to concentrate on its ChemPass AI™ platform, divesting non-core assets such as Lavie Bio and licensing Biomica's lead oncology candidate. The company has expanded its collaboration with Google Cloud to integrate advanced AI agents into ChemPass AI™ to accelerate small-molecule discovery. Ofer Haviv serves as the President and CEO, guiding the company's efforts to translate generative AI discoveries into commercially viable products through strategic partnerships and internal expertise.

Latest updates

Evogene Faces Nasdaq Delisting Risk Amidst Sub-$1 Share Price

Event summary

  • Evogene received a Nasdaq notification indicating non-compliance with Nasdaq Rule 5550(a)(2) due to a share price below $1.00 for 30 consecutive trading days.
  • The company has until September 28, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive trading days.
  • Failure to comply may lead to delisting, with a potential extension of up to 180 days possible if certain requirements are met.
  • Evogene is considering options to regain compliance, including a potential reverse stock split.

The big picture

Evogene's situation highlights the challenges faced by smaller biotech companies reliant on computational chemistry, particularly those operating in volatile markets. The Nasdaq notification underscores the importance of maintaining a healthy share price and market capitalization to retain listing status, and the potential for a reverse stock split signals a significant effort to address the immediate issue. The company's ability to execute on its technology and partnerships will be paramount in restoring investor confidence and avoiding delisting.

What we're watching

Reverse Split
The likelihood of Evogene pursuing a reverse stock split will depend on investor sentiment and the company's ability to demonstrate a clear path to profitability and share price recovery.
Financial Health
Evogene's ability to maintain sufficient working capital and secure additional funding will be critical to navigating the compliance period and avoiding delisting.
Product Pipeline
The success of Evogene's product pipeline, particularly its ability to generate revenue from its ChemPass AI platform, will be a key driver of investor confidence and share price performance.

Evogene to Detail AI Drug Discovery Advances at BIO-Europe Spring

Event summary

  • Evogene will present at BIO-Europe Spring 2026 in Lisbon, Portugal, from March 23-25, 2026.
  • Dr. Olga Nissan, VP Business Development, will deliver an oral presentation on March 24, 2026, at 15:30 WET.
  • The presentation will focus on advancements in Evogene’s AI-driven small-molecule discovery and optimization using ChemPass AI™.
  • Dr. Gabi Tarcic, Chief Development Officer, and Dr. Nissan will be available for one-on-one meetings.

The big picture

Evogene's focus on generative AI for drug discovery aligns with the broader trend of leveraging artificial intelligence to accelerate pharmaceutical R&D and reduce costs. The company's reliance on ChemPass AI™ positions it within a competitive landscape of computational chemistry firms, and its ability to secure partnerships and demonstrate tangible results will be critical for long-term viability. The company's exposure to geopolitical risk in the Middle East adds a layer of complexity to its investment profile.

What we're watching

Partnerships
The success of Evogene's collaborative drug discovery model hinges on securing and retaining partnerships with established pharmaceutical and biotech firms, and the conference provides a key opportunity to assess the progress of those relationships.
Geopolitical Risk
The company's forward-looking statements explicitly mention the ongoing geopolitical instability in the Middle East, which could significantly disrupt operations and supply chains, and will be a key factor in investor sentiment.
ChemPass AI
The efficacy of ChemPass AI™ in consistently generating viable drug candidates will dictate Evogene’s ability to move beyond early-stage development and achieve commercial success, and the conference presentation will offer insights into its performance.

Evogene Sharpened Focus on AI-Driven Molecule Design Drives Cost Cuts

Event summary

  • Evogene underwent a strategic shift in 2025, concentrating on its ChemPass AI™ platform for small-molecule discovery and optimization.
  • The company discontinued non-core activities, divested subsidiaries Lavie Bio (acquired by ICL) and Biomica (licensed assets to Lishan Pharmaceuticals), and resized its organization.
  • Evogene collaborated with Google Cloud, achieving a 90% design precision benchmark with a foundation model trained on 38 billion structures.
  • Operating expenses decreased significantly, from $22.0 million in 2024 to approximately $13.8 million in 2025, driven by the restructuring and divestitures.
  • Revenues decreased from $5.6 million in 2024 to $3.9 million in 2025, primarily due to reduced activity from AgPlenus and Casterra.

The big picture

Evogene's strategic pivot reflects a broader trend in the biotech and ag-tech sectors towards specialization and leveraging AI to accelerate discovery and reduce R&D costs. The company's decision to divest non-core assets and focus on ChemPass AI™ represents a bet on generative AI's ability to disrupt traditional molecule design processes. The success of this strategy will depend on Evogene's ability to secure and execute partnerships, and demonstrate a clear return on investment from its concentrated efforts.

What we're watching

Commercial Traction
The success of Evogene's focused strategy hinges on the ability to translate ChemPass AI™ into commercially viable drug and agricultural product candidates, and the pace at which these collaborations yield revenue.
Google Dependency
Evogene's reliance on Google Cloud for AI infrastructure and development poses a risk if the partnership weakens or costs increase.
Casterra Performance
The performance of Casterra’s Brazilian operations will be critical to demonstrating the viability of the retained activities and offsetting the impact of the Kenya shutdown.

Evogene Sharpening Focus on AI-Driven Molecule Design After Strategic Overhaul

Event summary

  • Evogene underwent a strategic transformation in 2025, focusing on its ChemPass AI™ platform.
  • The company narrowed its focus to two markets: human health (small-molecule therapeutics) and agriculture (agrochemicals).
  • Evogene divested non-core subsidiaries, including Lavie Bio (acquired by ICL) and licensed Biomica's lead candidate to Lishan Pharmaceuticals.
  • ChemPass AI™ is built on a 38-billion-molecule universe and has reportedly discovered development-candidate predictions now in testing with partners.
  • Evogene has established a business development team aligned with its refined strategy and is collaborating with Google Cloud.

The big picture

Evogene's strategic shift reflects a broader trend in the pharmaceutical and agricultural industries towards leveraging AI and computational chemistry to accelerate drug and agrochemical discovery. The company's focus on ChemPass AI™ and its partnerships with industry giants like Bayer and Corteva position it to capitalize on this trend, but also expose it to the risks associated with nascent technologies and geopolitical instability. The divestitures suggest a recognition that previous diversification efforts were not yielding sufficient returns.

What we're watching

Partnership Scale
The success of Evogene's strategy hinges on the ability to secure and expand partnerships in both human health and agriculture; the disclosed four collaborations need to translate into meaningful revenue and product pipeline growth.
ChemPass Validation
The efficacy of ChemPass AI™ beyond the initial collaborations will be critical; the platform's ability to consistently generate viable drug and agrochemical candidates needs to be demonstrated.
Geopolitical Risk
Ongoing geopolitical instability in the Middle East, as noted in the forward-looking statements, could significantly disrupt Evogene's operations and supply chains, impacting its ability to execute its strategic plan.

Evogene Partners with QUT to Tackle Lung Cancer Resistance with AI

Event summary

  • Evogene is collaborating with Queensland University of Technology (QUT) to develop AI-driven therapeutics for chemotherapy-resistant non-small cell lung cancer (NSCLC).
  • The collaboration leverages Evogene’s ChemPass AI™ platform and Dr. Mark Adams’ research on a novel cellular detoxification pathway driving Cisplatin resistance.
  • Up to 70% of NSCLC patients treated with Cisplatin experience resistance, highlighting the need for alternative therapies.
  • The partnership will focus on identifying druggable mechanisms and generating small-molecule inhibitors to restore treatment sensitivity.

The big picture

Chemotherapy resistance remains a major obstacle in cancer treatment, driving a significant need for innovative therapeutic approaches. Evogene’s collaboration with QUT represents a strategic move to leverage AI-driven drug design to address this challenge, potentially expanding its technology beyond agricultural applications and into a high-value oncology market. The partnership’s focus on a specific, previously unrecognized detoxification pathway suggests a targeted approach that could offer a differentiated therapeutic option.

What we're watching

Clinical Validation
The success of this collaboration hinges on the ability to translate the identified cellular pathway into a clinically effective therapeutic target, which will require rigorous preclinical and clinical validation.
AI Integration
The iterative refinement of ChemPass AI™ with biological insights from Dr. Adams’ lab will be critical; the platform's ability to incorporate complex biological data will determine the quality of drug candidates generated.
Competitive Landscape
Given the significant unmet need in overcoming chemotherapy resistance, Evogene will face competition from other companies pursuing novel therapeutic strategies in NSCLC and other cancers.

Evogene Secures $3.4 Million via Warrant Exercise, Issues New Warrants

Event summary

  • Evogene has secured approximately $3.4 million in gross proceeds through the immediate exercise of existing warrants.
  • The proceeds will be used for working capital and general corporate purposes.
  • In exchange for the warrant exercise, Evogene issued new unregistered warrants (Series A-1 and Series B-1) with an exercise price of $1.25 per share.
  • The warrant inducement agreement involved an existing institutional investor.
  • A registration statement will be filed with the SEC to cover the resale of shares issued upon exercise of the new warrants.

The big picture

Evogene's reliance on warrant inducement transactions to raise capital highlights the challenges faced by smaller, computationally-focused biotech firms in securing funding. While the $3.4 million provides near-term runway, the structure of the deal—issuing new warrants—indicates a need to continually manage shareholder dilution and access to public markets. The company’s ChemPass AI platform remains central to its value proposition, but its commercial success will ultimately determine its ability to secure more conventional funding sources.

What we're watching

Investor Relations
The reliance on existing investors for this financing suggests potential limitations in broader market appeal, and future capital raises may require more diverse sources.
Dilution Risk
The issuance of new warrants, while providing immediate capital, introduces potential future dilution for existing shareholders if the warrants are exercised.
SEC Registration
The timeline and outcome of the SEC registration process will be critical for allowing resale of the underlying shares and could impact investor liquidity.

Evogene Integrates AI Agents into ChemPass AI™ via Expanded Google Cloud Collaboration

Event summary

  • Evogene and Google Cloud are expanding their collaboration, initially announced in October 2024.
  • The focus is on integrating AI agents into Evogene’s ChemPass AI™ platform using Google Cloud’s Vertex AI.
  • The first phase of the collaboration built a generative AI foundation model for ChemPass AI™.
  • The integration aims to accelerate small-molecule discovery and optimization for pharmaceuticals and agriculture.
  • Evogene plans to explore making its innovation tools accessible via the Google Cloud Marketplace.

The big picture

Evogene's collaboration with Google Cloud represents a broader trend of computational chemistry companies leveraging generative AI and cloud infrastructure to accelerate drug and ag-chemical discovery. The shift towards autonomous discovery workflows, as highlighted by Evogene's CEO, signifies a move away from traditional, resource-intensive R&D models. This partnership positions Evogene to capitalize on the growing demand for AI-powered solutions in the life sciences, but its success hinges on the practical application and scalability of the integrated platform.

What we're watching

Execution Risk
The successful integration of AI agents into ChemPass AI™ is crucial; any delays or technical challenges could impact Evogene’s timelines and partnerships.
Market Adoption
The willingness of pharmaceutical and agricultural companies to adopt Evogene’s AI-driven discovery platform will determine the long-term value of this collaboration.
Competitive Landscape
The emergence of competing AI-driven molecular design platforms could erode Evogene’s competitive advantage if ChemPass AI™ fails to maintain a technological lead.

Evogene Bolsters AI Drug Discovery with Key Scientific Advisory Appointments

Event summary

  • Evogene appointed Professors John J. Irwin (UCSF) and Dan T. Major (Bar-Ilan University) to its Scientific Advisory Board (SAB) on February 9, 2026.
  • Both appointees are recognized experts in computational chemistry and molecular modeling, with extensive publication records and impactful contributions to the field.
  • The appointments are intended to guide the development and refinement of Evogene’s proprietary AI platform, ChemPass AI™.
  • ChemPass AI™ is designed to accelerate the discovery and optimization of small molecules for drug development and agricultural chemical innovation.

The big picture

Evogene's move to bolster its scientific leadership underscores the growing reliance on AI and computational chemistry in drug and ag-chemical discovery. The industry is facing increasing pressure to reduce R&D costs and timelines, and AI-driven platforms like ChemPass AI™ represent a potential solution. However, the success of these platforms hinges on the quality of the underlying algorithms and the expertise guiding their development, making the SAB appointments a strategic signal of Evogene's commitment to this approach.

What we're watching

Technology Validation
The effectiveness of the SAB’s guidance will be critical in validating ChemPass AI™’s ability to consistently deliver novel and viable drug candidates, and whether the platform can move beyond theoretical potential to demonstrable results in real-world applications.
Competitive Landscape
The addition of these prominent researchers may attract increased scrutiny and competition within the AI-driven drug discovery space, potentially accelerating the development of competing platforms and impacting Evogene’s market share.
Integration Risk
The successful integration of Prof. Irwin and Prof. Major’s expertise into Evogene’s existing R&D processes will be key; misalignment or friction could hinder the platform's advancement and limit the impact of these appointments.

Evogene Partners with Unravel to Tackle Demyelinating Disease with AI-Driven Drug Design

Event summary

  • Evogene and Unravel Biosciences have initiated a collaboration to develop a first-in-class therapy for demyelinating disorders, including Multiple Sclerosis.
  • The partnership leverages Evogene's ChemPass AI generative chemistry platform and Unravel's BioNAV™ predictive biology platform and Living Molecular Twins™ patient datamine.
  • Unravel's platform has identified a novel demyelination target, which Evogene will use to design and optimize small-molecule inhibitors.
  • The collaboration aims to restore myelin and improve neurological function, an area where current therapies have limited efficacy.

The big picture

The collaboration represents a growing trend of combining AI-driven target identification with generative chemistry to accelerate drug discovery, particularly in areas with high unmet need like neurodegenerative diseases. The global market for MS therapies exceeds $13 billion annually, and the lack of effective myelin repair therapies creates a significant opportunity for a breakthrough treatment. Evogene's reliance on Unravel's target validation introduces a degree of dependency, but also potentially de-risks their generative AI platform.

What we're watching

Clinical Validation
The success of this collaboration hinges on Unravel’s ability to validate the novel target and demonstrate efficacy in preclinical models, a historically challenging area for demyelination therapies.
ChemPass AI
The effectiveness of Evogene’s ChemPass AI in designing brain-penetrant molecules that effectively target the identified mechanism will be critical to the program's advancement.
Regulatory Pathway
Given the complexity of neurological disorders and the potential for novel mechanisms of action, the regulatory pathway for any resulting therapy will likely be lengthy and require significant data to support approval.

Evogene Appoints Pharma Veteran to Drive Business Development

Event summary

  • Evogene appointed Dr. Olga Nissan as Vice President of Business Development, effective January 1, 2026.
  • Dr. Nissan previously served as CEO and Co-Founder of Protica Bio, and held roles at EcoPhage, BiomX, and Teva Pharmaceutical Industries.
  • She holds a PhD and postdoctoral research experience from the Weizmann Institute of Science.
  • Evogene’s CEO, Ofer Haviv, highlighted Dr. Nissan’s experience in AI-enabled drug discovery and company building.
  • The appointment aims to scale Evogene’s small-molecule discovery and optimization offering, powered by its ChemPass AI engine.

The big picture

Evogene’s move to bring in a seasoned executive like Dr. Nissan signals an acceleration of its business development efforts, reflecting the growing interest in AI-driven drug discovery. The company’s focus on small molecule design positions it within a competitive landscape, where speed and efficiency are critical for success. Dr. Nissan’s experience across multiple sectors suggests a deliberate effort to diversify Evogene’s revenue streams and mitigate risk.

What we're watching

Partnership Impact
The success of Evogene’s expansion will hinge on Dr. Nissan’s ability to forge and manage strategic partnerships, given the company’s reliance on collaborations for product development.
ChemPass Adoption
The rate at which Evogene can integrate ChemPass AI into its workflows and demonstrate tangible results will be a key indicator of the platform’s value proposition.
Geopolitical Risk
The ongoing conflict in Israel and its potential escalation could significantly disrupt Evogene’s operations and collaborations, impacting the timeline for Dr. Nissan’s initiatives.
CID: 560